Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

January 15, 2006 (Vol. 26, No. 2)

DeveloGen Tackles Metabolic Disorders

Developing Techniques for the Protection and Stimulation of Beta Cells

  • German biopharmaceutical company DeveloGen (www. develogen.com) initiated European Phase III trials with its lead diabetes immunotherapy product, DiaPep277.The company also recently presented positive results from two Phase II trials of DiaPep277 in type 1 diabetes patients. The two trials, including a one-year extended safety and efficacy study, indicate that ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.